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Prenatal Testing for Subchromosomal Abnormalities
Kitty K. Lo,1 Evangelia Karampetsou,2 Christopher Boustred,2 Fiona McKay,2 Sarah Mason,2
Melissa Hill,2 Vincent Plagnol,1 and Lyn S. Chitty2,3,*
The use of massively parallel sequencing of maternal cfDNA for non-invasive prenatal testing (NIPT) of aneuploidy is widely available.
Recently, the scope of testing has increased to include selected subchromosomal abnormalities, but the number of samples reported has
been small. We developed a calling pipeline based on a segmentation algorithm for the detection of these rearrangements in maternal
plasma. The same read depth used in our standard pipeline for aneuploidy NIPT detected 15/18 (83%) samples with pathogenic rear-
rangements > 6 Mb but only 2/10 samples with rearrangements < 6 Mb, unless they were maternally inherited. There were two
false-positive calls in 534 samples with no known subchromosomal abnormalities (specificity 99.6%). Using higher read depths, we
detected 29/31 fetal subchromosomal abnormalities, including the three samples with maternally inherited microduplications. We
conclude that test sensitivity is a function of the fetal fraction, read depth, and size of the fetal CNV and that at least one of the two
false negatives is due to a low fetal fraction. The lack of an independent method for determining fetal fraction, especially for female
fetuses, leads to uncertainty in test sensitivity, which currently has implications for this technique’s future as a clinical diagnostic
test. Furthermore, to be effective, NIPT must be able to detect chromosomal rearrangements across the whole genome for a very low
false-positive rate. Because standard NIPT can only detect the majority of larger (>6 Mb) chromosomal rearrangements and requires
knowledge of fetal fraction, we consider that it is not yet ready for routine clinical implementation.Introduction
Unbalanced chromosomal rearrangements, including
those in microdeletion and microduplication syndromes,
are associated with a range of adverse phenotypes and
are individually rare. Although the overall incidence is un-
known, it is thought that the combined incidence might
approach that of Down syndrome (trisomy 21 [MIM
190685]).1,2 The majority of cases occur randomly, but
some, for example, those in DiGeorge syndrome
(22q11.2 deletion [MIM: 188400]), Cri du chat syndrome
(5p deletion [MIM: 123450]), and Charcot-Marie-Tooth
type 1A disease (17p11.2 duplication [MIM: 118220]), are
recurrent. Unlike Down syndrome, these other rearrange-
ment disorders do not have a universal prenatal screening
program, although they might be found more commonly
in fetuses with an increased nuchal translucency or other
fetal abnormalities.1,3,4 Currently, prenatal diagnosis of
such rearrangements requires an invasive procedure,
such as chorionic villus sampling or amniocentesis fol-
lowed by karyotyping or microarray analysis.
Since2011, theuseofmassivelyparallel sequencing (MPS)
of cell-free DNA (cfDNA) in maternal plasma for non-inva-
sive prenatal testing (NIPT) of fetal aneuploidies has become
available in more than 60 countries.5 Most national and in-
ternational organizations now recognize NIPT as a highly
sensitive screening test that can reduce theneed for invasive
testing when it is used in high-risk pregnancies.6–8 Over the
same time period, there has been a move to replace tradi-
tional karyotyping following invasive testing with microar-1UCLGenetics Institute, University College London, London,WC1E 6BT, UK; 2
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chromosomal rearrangements to include microdeletion
and microduplication syndromes.1,2,4 There are concerns
that widespread implementation of NIPT stands to decrease
the detection of these other pathogenic rearrangements.10
However, in principle, sequencing of cfDNA can also be
used for detecting other unbalanced chromosomal rear-
rangements prenatally, and a number of proof-of-concept
studies using a variety of sequencing depths and bioinfor-
matics approaches have detected a range of fetal subchro-
mosomal abnormalities in maternal plasma.11–15 Indeed,
several commercial providers have expanded their NIPT
platform to include a panel of syndromes characterized by
recurrent microdeletions and microduplications.
The statistical power of the methods published to date is
a function of the read depth and the size of the fetal copy-
number variants (CNVs). Using one billion reads, Sriniva-
san et al. detected fetal CNVs as small as 300 kb,14 whereas
Chen et al. claimed that their pipeline can detect all fetal
CNVs bigger than 10 Mb with just two to eight million
reads.13 Until now, NIPT of subchromosomal abnormal-
ities has been reported only in a small number of cases of
affected pregnancies, although a larger series using spiked
samples has been reported.16 The lack of datamakes it diffi-
cult to accurately determine the test sensitivity and speci-
ficity and, more importantly, the positive and negative
predictive values, which are crucial if this is to be imple-
mented in clinical practice.
Algorithms for detecting subchromosomal abnormalities
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approach, which looks for abnormalities in known loca-
tions,15,16 and the whole-genome approach, which can be
applied in situations where the location and size of the fetal
CNVs are not known13,14 and where read counts higher or
lower than those of the reference set can indicate the pres-
enceofCNVs.Here,wepresent results for a seriesofmaternal
plasma samples from pregnancies with known subchromo-
somal abnormalities occurring across the genome and
explore the potential for routine implementation.Material and Methods
Maternal blood samples were collected from women undergoing
invasive procedures for clinical indications in 40 maternity clinics
around the UK as part of the RAPID (Rapid Accurate Prenatal Non-
invasive Diagnosis) project. The study was approved by the local
research ethics committee (01/0095). Prior to invasive testing,
women were asked to consent to the withdrawal of 20–30 ml of
maternal blood to be placed in EDTA or in cell-stabilizing blood-
collection tubes when there was an anticipated transit delay of
more than 24 hr. Samples were centrifuged (3,000 rpm [1,000 3
g] for 15 min followed by 14,000 rpm for 10 min) for separating
the plasma, which was then stored in 2 ml aliquots at 80C.
For the purpose of this study, 4 ml plasma was defrosted and
cfDNAwas extracted with the QIAsymphony DSP Virus/Pathogen
Midi Kit and a custom protocol on the QIAsymphony (Qiagen)
and then sequenced with the Illumina HiSeq 2500 system with
single-end 50 bp reads. After sequencing, reads were aligned to
the human reference genome (UCSC Genome Browser hg19)
with Bowtie (see Web Resources). Only reads that uniquely map-
ped with no mismatches were retained.
In this study, 31 test samples with known unbalanced chromo-
somal rearrangementswere selected fromtheRAPIDproject sample
set. The clinical outcomeswere determined by conventional karyo-
typing, fluorescence in situ hybridization (FISH), microarray, or
molecular techniques such as multiplex ligation-dependent probe
amplification (MLPA) for clinical indications. The samples in our
study had fetal CNVs ranging in size from less than 3 Mb to
42 Mb on a number of different chromosomes. There were also
three cases of unbalanced translocations. Table 1 details the test
samples, including themethodused for determining the karyotype
and the gestational age at the time of sample collection. In addition
to sequencing the test samples, we also sequenced 534 known
euploid samples (hereafter referred to as the reference set) accord-
ing to the same parameters. For these 534 samples, invasive testing
had been performed for clinical indications, and results were avail-
able after karyotyping (506 samples) or rapid aneuploidy screening
via FISH or quantitative fluorescence PCR (QF-PCR) (28 samples).
The test samples were first sequenced at 12-plex (24 samples to a
flow cell), which was the same read depth as that of our standard
in-house pipeline for aneuploidy NIPT. For samples where no
anomaly was detected, re-sequencing at a higher depth across
multiple additional 1.5-plex runs (three samples per flow cell)
was performed until the CNV was detected. The highest read
depth was ~120 million reads per sample.Bias Correction
It iswell known that the PCRprocess introduces a bias related to the
GC content of the read count. To remove this bias, we used a two-
step process, available in the RAPIDR software package.17 First, weThe Abinned read counts into 20 kb lots and removed bins with zero
counts, unusually high counts, or counts in known CNV regions.
After binning, we adjusted the counts in each bin by a factor of
W ¼ M=Mi, where M is the average read count in all bins, and Mi
is the average read count in each 0.5% of GC content.18
After this first correction step, we applied principal-component
analysis (PCA) to remove some of the residual bias. PCA does not
require prior knowledge of the cause of the bias; rather, it assumes
that the systematic noise is from the largest components of vari-
ance in the principal components. Krumm et al. used a similar
technique to find CNVs in whole-exome sequencing.19 To
perform PCA, we normalized binned read counts across samples
by computing the ratio of the binned count over the total read
count for each sample. Given N samples and k bins, we con-
structed an N 3 k matrix X, in which each entry is the mean-
centered binned-count ratio for bin k in sample N. PCA decom-
poses the covariance matrix XXT ¼ WLWT , where W is a matrix
of eigenvectors of XXT . By using the matrix W determined from
the reference set, we rotated the test-sample data, T, onto the
same basis, T0 ¼ TW, and reconstructed the test set by subtracting
the top L components. For this analysis, we subtracted contribu-
tions from the first ten principal components.Segmentation Algorithm
The goal of a segmentation algorithm is to segment an ordered
data set, Y1:n ¼ {Y1, Y2, . Yn}, with m  1 change points, t1:m  1
¼ {t1, . tm  1}, such that the cost function,
CðYÞ ¼ Pmi¼1½CðYti1þ1:ti Þ, is minimized. From a computational
standpoint, the challenge is to effectively consider all change-
point locations (for our problem, this translates to all possible
locations for the CNV calls). We modeled our count data as a
beta-binomial distribution and used the following cost function:
C

Ytiþ1:tj

¼ log

P

Ytiþ1:tj
 jYi  betabin

Api;f
þ FðAÞ þ b:
Here, pi is the proportion of counts in bin i (which we determine
by taking themean of the counts in bin i [Ri] and dividing it by the
total counts for samples in the reference set), A is the ratio between
the counts in the test sample and the counts in the reference set
(A ¼ sum(Yi:j)/sum(Ri:j)), f is the dispersion parameter estimated
for each sample with the binned counts in all chromosomes,
F(A) in the cost function associated with the fetal fraction, and b
is another penalty term based on the Bayesian information crite-
rion and is defined as b ¼ 2 logðkÞ, where k is the number of bins.
We based our search on the pruned exact linear time (PELT)
algorithm,20 which is fast (close to linear time in the number of
observations) and finds the near-optimal change points. The
computational speed-up of PELTcomes from using a dynamic pro-
gramming approach and pruning the solution space in each step.
We performed the analysis by using R software21 with the RAPIDR-
Plus package.Segment Filtering
For samples with more than one segment per chromosome, we
used a likelihood-ratio test to test whether each segment was likely
to be a real fetal CNV. We summed the read count across the bins
that lay within the location of the potential CNV and used a beta-
binomial distribution to model the counts. The beta-binomial dis-
tribution is also known as a dispersed binomial distribution and
can be parameterized with p (from the binomial distribution)
and f (the dispersion parameter). For each potential CNVmerican Journal of Human Genetics 98, 34–44, January 7, 2016 35
Table 1. Tested Samples Ordered by CNV Size, Sequencing Detection, and Fetal-Fraction Estimation
Sample
No. Outcome
CNV Size
(Mb)a
How Outcome
Was Determined
Gestation
(Weeks þ Days) CNV Position (kb)
Sequencing Detection Implied Fetal Fraction
12-Plex Deeper From CNV From Chr Y
1470 47,XY,þidic(9)(pter/q21.1::q21.1/pter) ~42 karyotype 12 þ 2 dup9: 1–72,100 yes not done 7.5% (15.1%)b 9.7%
8048 47,XX,þdel(9)(q11) ~42 karyotype 27 þ 1 dup9: 1-71,200 yes not done 31.8% –
7851 47,XY,þder(22)t(9;22)(p13;q11.2)mat chr9: ~42 karyotype 11 þ 6 dup9: 1–72,600 yes not done 7.2% 6.8%
chr22: ~3 dup22: 17,300–21,000 no 8.2%
5216 46,XX,del(13)(q22) ~40 karyotype 11 þ 5 del13: 83,600–115,000 no yes 4.6% –
12317 46,XX,del(4)(p15.2) ~26 karyotype 24 þ 2 del4: 1–25,200 yes not done 11.7% –
2092 46,XX,der(4)ins(14;4)(q13:q25q21.3)mat chr4: ~25 karyotype 11 þ 5 del4: 85,900–109,500 yes not done 13.8% –
10853 46,XY,del(2)(p23p25.1) ~25 karyotype 24 þ 1 del2: 11,000–28,400 yes not done 16.8% 18%
11660 46,XX,der(7)t(4;7)(p15.3;q34)pat chr4: ~17 karyotype 13 þ 2 dup4: 1–16,800 yes not done 8.2% –
chr7: ~20 chr7 not detected no
R-01071 46,XY,del(4)(p15.32) ~18 karyotype 21 þ 0 del4: 1–15,600 no yes 4.6% 5.3%
13122 46,XX,dup(21)(q21.2q22.2) ~16 karyotype 20 þ 0 dup21: 25,800–41,400 yes not done 9.2% –
21 46,XX,del(5)(p15.1)dn ~15 karyotype 14 þ 0 del5: 1–15,500 yes not done 19.2% –
12279 46,XY,del(18)(p11.1).arr
18p11.32p11.21(149,080–14,007,190)31
13.8 karyotype and microarray 18 þ 2 del18: 1–18,700 yes not done 7.8% 7.7%
dup18: 18,700–78,000 9.0%
R-01025 46,XX,del(9)(p23)dn.ish del(9)(34H2,RP11-
165F24)
~13 karyotype and FISH 17 þ 3 del9: 1–16,800 yes not done 11.9% –
12344 arr 15q26.1q26.3(91,836,928–102,481,320)31 11 microarray 28 þ 4 dup15: 34,400–90,100 yes not done 14.8% 15.8%
del15: 90,100–102,300
1144 46,XX,der(18)t(12:18)(p13.1;q23)pat chr12: ~12 karyotype 17 þ 1 dup12: 1–9,400 yes not done 8.8% –
chr18: ~5 del18: 72,300–78,000 8.0%
10855 46,XX,del(1)(q41q42) ~12 karyotype 13 þ 2 not detected no no – –
R-00940 46,XX,der(7)(pter/q36.1::?q36.1/
q36.1::p21/pter)dn.ish der(7)?
dup(7)(q36.1/q36.1)(RP11-4340þþ)
del(7)(q36.3/qter)(RP11-6903,c3K23)
dup(7)(p21/pter)(c109A6þ)
~10 karyotype and FISH 12 þ 5 dup7: 1–16,500 yes not done 7.7% –
del7: 152,700–159,100 11.5%
9639 46,XY,del(6)(p25) ~7 karyotype 21 þ 2 del6: 1–7,400 yes not done 15.8% 20%
R-01716 46,XX,add(6)(p25).ish
del(6)(p25.3p25.3)(CTB-62I11,RP11-
118B18).arr[hg18] 6p25.3p25.1(77,025–
5,820,602)31
5.7 karyotype, FISH, and microarray 21 þ 0 del6: 1–6,400 yes not done 17.3% –
(Continued on next page)
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Table 1. Continued
Sample
No. Outcome
CNV Size
(Mb)a
How Outcome
Was Determined
Gestation
(Weeks þ Days) CNV Position (kb)
Sequencing Detection Implied Fetal Fraction
12-Plex Deeper From CNV From Chr Y
R-00875 46,XX,del(5)(p15.33)dn.ish
del(5)(p15.33)(c84C11,RP11-348B13,RP11-
129I19,RP11-473F9þ,RP11-259D10þ)
~4.5 karyotype and FISH 17 þ 3 del5: 1–10,500 yes not done 9.7% –
10256 46,XY,ish del(8)(q24.3q24.3)(RP11-65A5).arr
8q24.3(140,186,782–144,969,635)31 dn
4.8 karyotype and microarray 13 þ 2 del8: 140,300–145,100 no yes 9.8% 9.2%
11600 46,XX dup within 17p12 ~1.5 karyotype and QF-PCR 11 þ 2 dup17: 14,600–16,000 no yes 10.2% –
8383 46,XY,dup(17)(p11.2p11.2).arr
17p11.2(16,637,872-20,294,010)33
3.7 karyotype and microarray 22 þ 0 dup17: 16,900–20,800 no yes 7.0% 5.8%
11590 46,XX dup within 17p12 inherited from the
mother
~1.5 karyotype and QF-PCR 11 þ 0 dup17: 14,200–15,900 yes not done – –
612 46,XX dup within 17p12 inherited from the
mother
~1.5 karyotype and QF-PCR 12 þ 6 dup17: 14,200–15,900 yes not done – –
R-00983 46,XY.ish del(22)(q11.2q11.2)(RP11-
1057H19)
<3 karyotype and FISH 21 þ 0 not detected no no – 2.5%
R-01012 46,XX.ish del(22)(q11.2q11.2)(RP11-
1057H19)
<3 karyotype and FISH 20 þ 4 del22: 18,600–22,000 no yes 8.2% –
12295 46,XX,del(22)(q11.2q11.2) <3 karyotype and BACs-on- Beads 12 þ 6 del22: 19,100–23,300 no yes 9.6% –
6876 46,XY.mlpa 22q11.2(P290)33 inherited from
the mother
<3 karyotype and MLPA 14 þ 1 dup22: 19,100–22,000 yes not done – 18%
13067 46,XY,del(22)(q11.2q11.2) <3 karyotype 28 þ 1 del22: 19,200–22,000 no yes 23.8% 23.5%
2493 46,XY.ish del(22)(q11.2q11.2)(TUPLE1)dn <3 karyotype and FISH 22 þ 2 del22: 19,200–22,000 no yes 13.4% 17.3%
Abbreviations are as follows: BAC, bacterial artificial chromosome; Chr, chromosome; CNV, copy-number variant; FISH, fluorescence in situ hybridization; MLPA, multiplex ligation-dependent probe amplification; and
QF-PCR, quantitative fluorescence PCR.
aThe ~ symbols mean that we can only provide an upper limit for the size estimate because of the limits of karyotyping.
bThis sample has an extra isodicentric chromosome 9; therefore, there are four total fetal copies of the region 9pter/9q21.1, and the fetal-fraction measurement is based on this. In parentheses is given the fetal-fraction
measurement if only three copies of this region are present in the fetus.
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Figure 1. Plots of Count Ratios Illustrate a Microduplication and a Microdeletion in Sample 1144
Dots are the counts divided by the expected counts of the reference set in 100 kb bins; the solid line is the output from the segmentation
algorithm.
(A) Microdeletion event in 18q23.
(B) Microduplication event in 12p13.1.segment, we used the reference set to find p and f and then calcu-
lated the log-likelihood-ratio test statistics by using
S ¼ 2 log LðY jY  betabinðp;fÞÞ
LðY jY  betabinðAp;fÞÞ;
where Y is the sum of counts within the CNV segment for the test
sample, and A is a scale parameter, which takes a value of greater
than 1 for duplications and less than 1 for deletions. Unlike the
simple Z score test used by NIPT for aneuploidy, the likelihood-ra-
tio test allows us to have different read depths between the refer-
ence set and the test set.
To call fetal CNVs, we used the following stringent set of criteria:
1. S > 30. Because 2log (likelihood ratio) statistics asymptot-
ically follow a chi-square distribution, this implies a p value
cutoff of 2 3 108.
2. 1.015 < A < 1.3 or 0.7 < A < 0.985. Values of A close to 0.5
or 1.5 indicate a maternal deletion or duplication, respec-
tively. A can be used for estimating the fetal fraction by
FF ¼ abs(1  A) 3 2. If A is very close to 1, it implies a low
fetal fraction. This filtering criterion implies a fetal-fraction
cutoff of 3%.
3. Segment length > 1 Mb.
Estimating the Fetal Fraction
For male fetuses, we used reads mapped to chromosome Y to esti-
mate the fetal fraction (Equation 5 from Rava et al.22). For samples
with CNV calls identified by our algorithm, we used the estimate
of A, as described in the previous section, to give an alternate esti-
mate of the fetal fraction (Table 1).
Power Calculation
The sensitivity of our method is a function of the read depth, the
size of the CNV, and the fetal fraction.We estimated the sensitivity38 The American Journal of Human Genetics 98, 34–44, January 7, 20as a function of fetal fraction by using estimates of the dispersion
parameter from fitting the counts to the beta-binomial distribu-
tion. Unlike previous simulation studies,13,15 which assumed no
technical bias and an ideal binomial distribution, our simulation
is more realistic because in the beta-binomial distribution, the
dispersion parameter accounts for some of the residual bias in
the data.Results
Sequencing at Four to Ten Million Reads
Sequencing at 12-plex yielded between four and ten
million reads per sample, and at this read depth, chromo-
somal rearrangements were detected in 20 out of 31 sam-
ples (Table 1). In samples with CNVs larger than 6 Mb, at
least one abnormality was detected in 15 out of 18 samples
(sensitivity ¼ 83% [95% confidence interval (CI) ¼ 61%–
94%]). For samples with CNVs smaller than 6 Mb, five
were detected, and three of them had duplications for
which the mother was a carrier. It is clear from the plots
of the normalized count ratios (Figure S1) that the CNVs
for these three samples are maternal, given that the
normalized count ratios are close to 1.5; however, using
our current bioinformatics pipeline and standard depth
of sequencing, we could not determine whether the fetus
also carried the CNV. Of the ten other samples with
CNVs smaller than 6 Mb, two were correctly identified
(sensitivity ¼ 20% [95% CI ¼ 6%–51%]). Table 1 shows a
summary of the results, including the locations of the
CNV calls, for all samples.
As an illustrative example, Figure 1 shows the normal-
ized count ratios for sample 1144, which had an16
AB
C
Figure 2. Plots of Count Ratios for Sample 12295 Illustrate How
Variance Decreases as Read Depth Increases
The three different read depths are 7 million (A), 32 million (B),
and 71 million (C).
The Aunbalanced translocation between chromosomes 12 and
18. Each point represents the read count in a 100 kb bin
divided by the expected read count as determined from
the reference set. The solid line is the output from the seg-
mentation algorithm; the elevated segment in chromo-
some 12 represents a gain of the terminal short arm with
a breakpoint at 12p13.1, and the depressed segment in
chromosome 18 represents a loss of the terminal long
arm with a breakpoint at 18q23. Plots of count ratios for
the other samples can be found in the Supplemental Data.
All segments called by our algorithm from the test
samples were true positives, except for a discordant result
for sample 12279. For this sample, karyotype and microar-
ray results showed a deletion of the short arm of chromo-
some 18, which was also called by our pipeline, but our
pipeline also found a duplication of the long arm of chro-
mosome 18.
The analysis pipeline was also tested on a set of 534 sam-
ples that had no known chromosomal abnormalities and
that had been sequenced with at least four million reads.
After filtering, there were three false calls in two samples
(specificity ¼ 99.6% [95% CI ¼ 98.6%–99.9%]). A false
call can be located in any genomic position and is not
confined to a specific region of interest. There were no false
calls in off-target genomic locations in any of the samples
with known microdeletions and/or microduplications.
Deeper Sequencing
Deeper sequencing correctly identified the fetal CNV in 9
of 11 samples where the imbalance had not been detected
by the standard shallow-sequencing pipeline. As expected,
variance in the count ratios decreased as read depth
increased, as demonstrated by one fetus with a 22q11.2
deletion, which was ultimately detected when the sample
was sequenced to a depth of 32 million reads (Figure 2).
In addition to identifying the CNVs, the pipeline indi-
cated locations that were highly accurate and matched
well with positions given by microarray analysis (Table 1;
Figure 3). For example, for sample 8383, our pipeline found
a fetal CNV in chr17: 16,900,000–20,800,000, which
matched the position obtained by genomic microarray
analysis (chr17: 16,637,872–20,294,010) to within
500 kb. Similarly, for sample 10256, microarray analysis
indicated a deletion in chr8: 140,186,782–144,969,635,
and the location given by our pipeline was chr8:
140,300,000–145,100,000 (Table 1). Plots of the count ra-
tios for samples 8383 and 10256 are shown in Figure 3.
CNVs in two samples were not detected by sequencing at
a higher read depth. The first sample (R-00983) was from a
male fetus with a 3 Mb deletion in 22q11.2. Using the
reads mapped to chromosome Y, the pipeline estimated
the fetal fraction to be 2.5% (Table 1). The second sample
(10855) was from a female fetus with a deletion of around
12 Mb on chromosome 1, and estimation of the fetal frac-
tion was not possible.
Inmale fetuses with positive CNV calls, the fetal-fraction
estimates from CNV calls and from chromosome Y weremerican Journal of Human Genetics 98, 34–44, January 7, 2016 39
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Figure 3. Comparison of the CNV Positions Derived from Microarray and Our Segmentation Algorithm
(A) Microduplication event of 3.7 Mb in 17p11.2.
(B) Microdeletion event of 4.8 Mb in 8q24.3.highly correlated; linear regression yielded an r2 of 0.92
(Figure 4).Power Calculation
Results of a simulation study for the detection power for a
3 Mb CNVand a 10Mb CNVat different fetal fractions and
read depths are shown in Figure 5. Because the power esti-
mation assumes a beta-binomial distribution for the
counts and uses an estimate of the dispersion parameter
that we derived from our data, our power estimation is spe-
cific to our laboratory, and others might find that they
have different residual bias in the read count. After ac-
counting for the residual bias, we found that the sensitivity
of the test did not improve much with a higher read depth
for a fetal fraction below 5%. On the other hand, CNVs as
small as 1Mb could be detected with 38million reads if the
fetal fraction was over 20%. Figure 6 illustrates empirically
the impact of fetal fraction and CNV size in our test sensi-
tivity by showing the number of reads required for detec-
tion in our dataset.Discussion
In this study, we demonstrated that NIPT for aneuploidy
can be used to detect the majority of pathogenic chromo-
somal rearrangements detectable by standard karyotyping.
Applying our refined bioinformatics pipeline can achieve
this without extra sequencing costs, given that we detected
15 out of 18 samples with fetal subchromosomal abnor-
malities larger than 6 Mb by using 12-plex sequencing
(sensitivity ¼ 83% [95% CI ¼ 61–94%] and specificity ¼
99.6% [95% CI ¼ 98.6%–99.9%]). Raising the read depth40 The American Journal of Human Genetics 98, 34–44, January 7, 20to 120 million reads increased the test sensitivity to 94%
(95% CI ¼ 74%–99%) for CNVs larger than 6 Mb and to
93% (95% CI ¼ 77%–98%) for CNVs larger than 1.5 Mb.
However, because our reference set was only sequenced
at 12-plex, it is not possible to estimate the test specificity
at the higher read depth. The cost of increasing the depth
of sequencing would be high, and the false-positive rate is
likely to increase. For fetuses with sonographic anomalies,
an invasive test might still offer the most accurate and
timely diagnosis because it is not possible to reliably
exclude the possibility of a false-negative result even with
deeper sequencing. One of the major perceived benefits
of NIPT for aneuploidy is the significantly reduced require-
ment for invasive testing23 and the consequent improved
safety, which women value most highly.24 Any change
that increases the false-positive rate will negate to some de-
gree this major benefit of NIPT screening. Given the rarity
of these other rearrangements, the costs of introducing
this testing (including economic costs, the potential loss
of pregnancies resulting from increasing the invasive-
testing rate, and the anxiety caused to parents) must be
weighed against the possible benefits.
Because of the considerable uncertainty in the preva-
lence of clinically relevant microdeletion and microdupli-
cation syndromes, it is difficult to estimate the positive
predictive value of our method. As a rough estimate, if
we consider the incidence of all microdeletion and micro-
duplication syndromes with CNVs larger than 6 Mb,
excluding aneuploidies, to be 0.6% amongst fetuses with
an indication,1 then our test, with a sensitivity of 83%
and a specificity of 99.6%, would have a positive predictive
value of 0.55. Expansion of NIPT to include detection of
these other rearrangements stands to decrease the16
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Figure 4. The Fetal-Fraction Estimates from CNVs Called by Our
Pipeline Are Closely Correlated with the Fetal-Fraction Estimates
from Chromosome Yspecificity and increase the invasive-testing rate. Our data,
therefore, support the American Committee of Obstetri-
cians and Gynecologists recommendation that routine
cfDNA aneuploidy screening should not be expanded to
include microdeletion syndromes.6
Our pipeline failed to detect three samples with CNVs >
6 Mb at 12-plex sequencing and, in one sample (12279),
gave a true-positive call, as well as what initially appeared
to be a false-positive call: a duplication of the whole long
arm of chromosome 18, whereas invasive testing of amni-
otic fluid showed that the sample had only a non-mosaic
deletion of the whole short arm of chromosome 18. Inter-
estingly, this sample had also undergone NIPT for aneu-
ploidy with a commercial company that reported it as
highly likely to have trisomy 18. Given that different pop-
ulations of cells are tested by NIPT (mainly cytotropho-
blasts) and amniocentesis (amniocytes and fetal cells),
the most likely explanation for this discrepant finding is
confined placental mosaicism, and our finding potentially
represents an isochromosome for 18q, i.e., the initial
conception either carried the deletion of 18p and the
deleted chromosome was duplicated via a U-type exchange
mechanism in the placenta or carried the 18q isochromo-
some (both the deletion of 18p and the duplication of
18q), of which one arm was then deleted and lost in the
fetus. Unfortunately, no placental material was available
for confirming this hypothesis. The maternal karyotype
was normal (46,XX), eliminating the possibility that a
mosaic maternal rearrangement complicated our prenatal
cfDNA result.
For samples with maternal duplications, our pipeline
with the standard depth of sequencing detected the micro-
duplication in all three samples but could not accurately
determine whether the fetus had inherited the microdupli-The Acation. In principle, the same counting statistics, when
given the fetal fraction, should be able to determine fetal
inheritance. If the fetus has inherited the microduplica-
tion, the expected count ratio is 1.5; if the fetus has not in-
herited the microduplication, the expected count ratio is
reduced to 1.5  fetal fraction/2. Achieveing sufficient ac-
curacy would require knowledge of the fetal fraction and
most likely a higher read depth.
Our standard sequencing depth for NIPT for aneuploidy
gave 12 false negatives, which included three false nega-
tives with CNVs larger than 6Mb.We detected two of these
samples with deeper sequencing and estimated their fetal
fraction to be less than 5%, indicating that a low fetal frac-
tion is likely to be the reason for failing to detect the
rearrangement. Figure 6 further highlights this issue.
Increasing the depth of sequencing increased the detection
rate of smaller CNVs. However, our power analysis showed
that it would be difficult for our test to achieve 100% sensi-
tivity, even for large CNVs, if the fetal fraction is low. With
100 million reads, we can achieve 99% sensitivity for
10MbCNVs with a 5% fetal fraction, but if ~5% of samples
have fetal fractions less than 5%,22 then the test’s overall
sensitivity will be reduced to ~94%. Clearly, estimating
the fetal fraction is crucial in the detection of CNVs, given
that a low fetal fraction might lead to a negative result
(Figure 6). For male fetuses, it might be possible to use
the fetal fraction estimated from chromosome Y to
constrain the minimum size of the detectable CNV. For fe-
male fetuses, alternative methods for estimating the fetal
fraction will be needed. One such technique is to use the
proportion of short reads to estimate the fetal fraction.25
The implication is that although standard NIPT with
MPSmight detect most of the large CNVs, a negative result
cannot rule out the possibility that a subchromosomal
CNV is present in the fetus because of a low fetal fraction.
Our method improves upon some of the previously pub-
lished techniques for detecting subchromosomal copy-
number changes in cfDNA. Some published methods bin
the read counts into 1 Mb bins and only call a CNV if
consecutive bins have Z scores above a certain value.14,15
The requirement for consecutive bins to pass statistical
tests is less powerful than summing the counts in all bins
covered by the CNV and then performing a statistical
test. Our method of binning into small, 100 kb bins and
then performing segmentation to find potential CNV seg-
ments offers higher statistical power. A decision tree is
another technique that has been referenced in the litera-
ture.26 Compared to our likelihood-ratio test, a decision
tree is not statistically robust and lacks interpretability.
The approach we have taken in this study does not
require prior knowledge of the fetal CNV’s location. The
alternative approach is to test for a panel of known recur-
rent microdeletion and microduplication syndromes, as
is now being done by a number of commercial com-
panies.16,26 By restricting the test to known regions, it
might be possible to decrease the test-statistic cutoff for
calling a CNV, thus improving sensitivity withoutmerican Journal of Human Genetics 98, 34–44, January 7, 2016 41
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Figure 5. Test Sensitivity for Deletions of Different Sizes
Deletions of 3 Mb (A) and 10 Mb (B). The dotted line assumes that the counts follow a binomial distribution, which is the theoretical
optimal sensitivity that can be achieved with the read-counting method; the solid line assumes that the counts follow a beta-binomial
distribution with f ¼ 108 for the 3 Mb deletion and f ¼ 3 3 108 for the 10 Mb deletion. f is the over-dispersion parameter, and it
captures the additional variance in the counts. The f we used in the simulation was derived from our dataset.sacrificing specificity, and thismight offer easier interpreta-
tion of positive results given that there would be no vari-
ants of unknown significance. However, this assumes
that we know the exact location of the CNV, and this
might not be the case. Most unbalanced rearrangements
are random, and a targeted approach would fail to detect
many rearrangements.27 Of the 225 pathogenic cytoge-
netic rearrangements detected by traditional karyotyping
in our laboratory over the past 15 years, only 62 (~25%)
would be detected by a targeted approach (E.K., unpub-
lished data). Furthermore, the size of many of these rear-
rangements can be very variable. As of yet, no data are
available to indicate what the limit of detection by
sequencing approaches might be, so the negative predic-
tive value cannot be determined, and confirming a nega-
tive result in a high-risk pregnancy would still require
invasive testing.
The main limitation of our technique is the lack of sensi-
tivity for CNVs of less than 6 Mb. A previous study showed
that microarray analysis detected clinically significant
CNVs, ~75% of which were smaller than 10 Mb, in up to
6.5% of fetuses with an ultrasound abnormality and
normal karyotype.2 No comprehensive data currently
give the true incidence of pathogenic CNVs < 6 Mb, and
thus it is difficult to determine exactly what proportion
of CNVs would be missed, but it is clear that a significant
number would not be detected. Comparing the efficacy
of the different diagnostic techniques and determining
the limits of detection would require a very large prospec-
tive study comparing NIPT and microarray analysis. We
have shown that deeper sequencing can improve sensi-42 The American Journal of Human Genetics 98, 34–44, January 7, 20tivity, albeit with a higher cost and the potential for detect-
ing more variants of unknown significance. Another
approach for increasing the detection rate for small CNVs
is to use capture technology. This would require designing
a capture panel around known common and/or recurrent
CNV locations and using bioinformatics to identify break-
points in the CNVs. This, too, is costly andwould also limit
detection to knownCNVs rather than genome-wide CNVs,
thereby limiting detection of pathogenic CNVs overall.
Conclusion
Wehave developed a calling algorithm that detects thema-
jority of cytogenetically visible chromosomal rearrange-
ments (>6 Mb) via standard sequencing used for trisomy
NIPT. It has amodest false-positive rate of 0.4%, but report-
ing a negative result requires an accurate assessment of the
fetal fraction. Microdeletions and microduplications of
<6 Mb cannot reliably be detected unless they are mater-
nally inherited or the depth of sequencing is increased
significantly, when the false-positive rate is likely to in-
crease. Even then, the negative predictive value cannot
confidently exclude a very small rearrangement. At pre-
sent, confidently excluding the presence of a pathogenic
CNV requires analysis of fetal genetic material obtained
from chorionic villus sampling or amniocentesis. Given
that a significant benefit of using NIPT to screen for aneu-
ploidy is the increased safety secondary to the reduced
need for invasive testing, extending NIPT to include
screening for subchromosomal rearrangements stands to
reverse some of this benefit whilst not offering compre-
hensive detection of pathogenic rearrangements. The costs16
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Fetal fraction were estimated from chromosome Y for male fetuses
or from the CNV detected for female fetuses. Missed detection for
female fetuses is not shown in this plot because we were unable to
estimate the fetal fraction.and benefits of extending NIPT to this indication should
be seriously considered prior to routine implementation.Supplemental Data
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